RPE65 and Chorioretinal atrophy: Unfortunately, significant perifoveal chorioretinal atrophy after subretinal gene therapy injection is now recognized as a common complication in human surgeries of voretigeneneparvovec-rzyl (Luxturna), a U.S. Food and Drug Administration–approved gene therapy for patients with biallelic RPE65 variants.36